Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Oct;70(4):719–723. doi: 10.1038/bjc.1994.382

Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.

M T Seymour 1, P W Johnson 1, M R Hall 1, P F Wrigley 1, M L Slevin 1
PMCID: PMC2033402  PMID: 7917927

Abstract

Twenty-nine patients with adenocarcinomas of gastrointestinal or unknown primary, and three with advanced neuroendocrine tumours, were entered into a study of bolus plus infusional 5-fluorouracil (FUra) modulated with high-dose leucovorin (LV) and recombinant interferon alpha 2a (IFN-alpha). Successive cohorts of > or = 4 patients received IFN-alpha at 1.5, 3, 4.5, 6 and 9 MU on alternate days throughout the treatment period. The FUra/LV regimen consisted of: LV 200 mg m-2 i.v. infusion over 2 h, FUra 400 mg m-2 i.v. bolus then FUra 400 mg m-2 i.v. infusion over 22 h, all repeated on day 2, on a 14-day cycle. FUra was given at 75% dose for the first course, increasing (in the absence of WHO grade > or = 2 toxicity) to 87.5% for the second and 100% for subsequent courses up to a maximum of 12. The maximum tolerated dose (MTD) of IFN-alpha was 6 MU on alternate days, with 7/8 patients at 9 MU requiring dose reductions. At 6 MU IFN-alpha, the MTD of FUra was not exceeded at 100% (i.e. 400 mg m-2 bolus and infusion, days 1 and 2), and FUra-related toxicities (mucosal, haematological, dermatological) were extremely mild. Twenty-nine patients were assessable for tumour response, among whom WHO criteria partial responses were seen in 7/14 with colorectal, 1/4 with gastric, 0/1 with pancreatic, 1/3 with neuroendocrine and 3/6 with unknown primaries. Median response duration was 51 weeks. Minor responses and stable disease were seen in a further six patients. Median survival of patients with advanced adenocarcinomas was 9 months, with 33% surviving beyond 18 months. This schedule offers a safe way of co-administering FUra, LV and IFN-alpha. The addition of IFN-alpha, while causing significant independent toxicity, does not significantly increase the dose-limiting mucosal toxicities of FUra/LV. Further investigation is required to determine the contribution of IFN-alpha to the anti-tumour activity of the combination.

Full text

PDF
719

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bukowski R. M., Inoshita G., Yalavarthi P., Murthy S., Gibson V., Budd G. T., Sergi J. S., Bauer L., Prestifilippo J. A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma. Cancer. 1992 Feb 15;69(4):889–892. doi: 10.1002/1097-0142(19920215)69:4<889::aid-cncr2820690409>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  2. Chu E., Zinn S., Boarman D., Allegra C. J. Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res. 1990 Sep 15;50(18):5834–5840. [PubMed] [Google Scholar]
  3. De Gramont A., Krulik M., Cady J., Lagadec B., Maisani J. E., Loiseau J. P., Grange J. D., Gonzalez-Canali G., Demuynck B., Louvet C. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol. 1988 Sep;24(9):1499–1503. doi: 10.1016/0277-5379(88)90341-0. [DOI] [PubMed] [Google Scholar]
  4. Elias L., Crissman H. A. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res. 1988 Sep 1;48(17):4868–4873. [PubMed] [Google Scholar]
  5. Elias L., Sandoval J. M. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun. 1989 Sep 15;163(2):867–874. doi: 10.1016/0006-291x(89)92302-4. [DOI] [PubMed] [Google Scholar]
  6. Grem J. L., Jordan E., Robson M. E., Binder R. A., Hamilton J. M., Steinberg S. M., Arbuck S. G., Beveridge R. A., Kales A. N., Miller J. A. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol. 1993 Sep;11(9):1737–1745. doi: 10.1200/JCO.1993.11.9.1737. [DOI] [PubMed] [Google Scholar]
  7. Grem J. L., McAtee N., Murphy R. F., Balis F. M., Steinberg S. M., Hamilton J. M., Sorensen J. M., Sartor O., Kramer B. S., Goldstein L. J. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol. 1991 Oct;9(10):1811–1820. doi: 10.1200/JCO.1991.9.10.1811. [DOI] [PubMed] [Google Scholar]
  8. Houghton J. A., Adkins D. A., Rahman A., Houghton P. J. Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells. Cancer Commun. 1991 Jul;3(7):225–231. doi: 10.3727/095535491820873236. [DOI] [PubMed] [Google Scholar]
  9. Houghton J. A., Morton C. L., Adkins D. A., Rahman A. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells. Cancer Res. 1993 Sep 15;53(18):4243–4250. [PubMed] [Google Scholar]
  10. Johnson P. W., Thompson P. I., Seymour M. T., Deasy N. P., Thuraisingham R. C., Slevin M. L., Wrigley P. F. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer. 1991 Sep;64(3):603–605. doi: 10.1038/bjc.1991.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kemeny N., Younes A., Seiter K., Kelsen D., Sammarco P., Adams L., Derby S., Murray P., Houston C. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer. 1990 Dec 15;66(12):2470–2475. doi: 10.1002/1097-0142(19901215)66:12<2470::aid-cncr2820661205>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  12. Lokich J. J., Ahlgren J. D., Gullo J. J., Philips J. A., Fryer J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989 Apr;7(4):425–432. doi: 10.1200/JCO.1989.7.4.425. [DOI] [PubMed] [Google Scholar]
  13. Neefe J. R., Glass J. Abrogation of interferon-induced resistance to interferon-activated major histocompatibility complex-unrestricted killers by treatment of a melanoma cell line with 5-fluorouracil. Cancer Res. 1991 Jun 15;51(12):3159–3163. [PubMed] [Google Scholar]
  14. Poon M. A., O'Connell M. J., Wieand H. S., Krook J. E., Gerstner J. B., Tschetter L. K., Levitt R., Kardinal C. G., Mailliard J. A. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol. 1991 Nov;9(11):1967–1972. doi: 10.1200/JCO.1991.9.11.1967. [DOI] [PubMed] [Google Scholar]
  15. Schwartz E. L., Hoffman M., O'Connor C. J., Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochem Biophys Res Commun. 1992 Feb 14;182(3):1232–1239. doi: 10.1016/0006-291x(92)91863-l. [DOI] [PubMed] [Google Scholar]
  16. Shah A., MacDonald W., Goldie J., Gudauskas G., Brisebois B. 5-FU infusion in advanced colorectal cancer: a comparison of three dose schedules. Cancer Treat Rep. 1985 Jul-Aug;69(7-8):739–742. [PubMed] [Google Scholar]
  17. Sinnige H. A., Buter J., de Vries E. G., Uges D. R., Roenhorst H. W., Verschueren R. C., Sleijfer D. T., Willemse P. H., Mulder N. H. Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin. Eur J Cancer. 1993;29A(12):1715–1720. doi: 10.1016/0959-8049(93)90111-r. [DOI] [PubMed] [Google Scholar]
  18. Wadler S., Schwartz E. L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 1990 Jun 15;50(12):3473–3486. [PubMed] [Google Scholar]
  19. Weinerman B., Shah A., Fields A., Cripps I. C., Wilson K., McCormick R., Temple W., Maroun J., Bogues W., Pater J. Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. Am J Clin Oncol. 1992 Dec;15(6):518–523. doi: 10.1097/00000421-199212000-00012. [DOI] [PubMed] [Google Scholar]
  20. Yee L. K., Allegra C. J., Steinberg S. M., Grem J. L. Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a. J Natl Cancer Inst. 1992 Dec 2;84(23):1820–1825. doi: 10.1093/jnci/84.23.1820. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES